Exobiosphere (in-orbit drug discovery and disease modeling) selected for Morgan Stanley Inclusive & Sustainable Ventures 2026 cohort (Health & Wellbeing theme), receiving an equity investment.
SEP 14, 2026
Exobiosphere is a space biotech advancing drug discovery and manufacturing in microgravity, using microgravity as a new dimension for biology to accelerate drug discovery and unlock therapies that are very hard or even impossible to develop on Earth
Exobiosphere is a space biotech advancing drug discovery and manufacturing in microgravity, using microgravity as a new dimension for biology to accelerate drug discovery and unlock therapies that are very hard or even impossible to develop on Earth. They are building the world’s first standardized space-based high-throughput testing platform, allowing pharma and biotech partners to run automated experiments in orbit, at scale.